Clinical Trial Update: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TNG260 in combination with an anti-PD antibody in STK11-mutated solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD antibody
• TNG260

Snippet

Sponsor: Tango Therapeutics, Inc. | Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult | Phase 1, Phase 2 | Status: RECRUITING